Tabula Rasa HealthCare ( ) - 株価, ニュースと分析Nasdaq:TRHC

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

TRHC 株式概要

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.

TRHC ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	1/6
過去の実績	0/6
財務の健全性	2/6
配当金	0/6

報酬

収益は年間13.23%増加すると予測されています

リスク分析

マイナスの株主資本

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Tabula Rasa HealthCare, Inc. 競合他社

Sharecare

NasdaqGS:SHCR

US$289.9m

MultiPlan

NYSE:MPLN

US$246.3m

Health Catalyst

NasdaqGS:HCAT

US$374.3m

OptimizeRx

NasdaqCM:OPRX

US$197.7m

価格と性能

の歴代最高値、変動、値下がりまとめTabula Rasa HealthCare
過去の株価
現在の株価	US$10.50
52週高値	US$10.50
52週安値	US$3.15
ベータ	1.58
11ヶ月の変化	1.16%
3ヶ月変化	34.10%
1年変化	203.47%
33年間の変化	-70.13%
5年間の変化	-85.61%
IPOからの変化	-29.44%

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

株主還元

	TRHC	US Healthcare Services	US 市場
7D	0.9%	-3.3%	0.4%
1Y	203.5%	-20.3%	22.9%

業界別リターン: TRHC過去 1 年間で-18.7 % の収益を上げたUS Healthcare Services業界を上回りました。

リターン対市場: TRHC過去 1 年間で20.8 % の収益を上げたUS市場を上回りました。

価格変動

Is TRHC's price volatile compared to industry and market?
TRHC volatility
TRHC Average Weekly Movement	8.6%
Healthcare Services Industry Average Movement	9.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

安定した株価: TRHCの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: TRHCの週次ボラティリティ ( 9% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2009	1,027	Brian Adams	www.tabularasahealthcare.com

Tabula Rasa HealthCare, Inc. 基礎のまとめ

Tabula Rasa HealthCare の収益と売上を時価総額と比較するとどうか。
TRHC 基礎統計学
時価総額	US$284.03m
収益（TTM）	-US$61.07m
売上高(TTM)	US$338.12m

0.8x

P/Sレシオ

-4.7x

PER（株価収益率

TRHC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
TRHC 損益計算書（TTM）
収益	US$338.12m
売上原価	US$258.28m
売上総利益	US$79.84m
その他の費用	US$140.91m
収益	-US$61.07m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-2.26
グロス・マージン	23.61%
純利益率	-18.06%
有利子負債／自己資本比率	-418.7%

TRHC の長期的なパフォーマンスは？

過去の実績と比較を見る

TRHC 株式概要

報酬

リスク分析

Tabula Rasa HealthCare, Inc. 競合他社

NasdaqGS:SHCR

US$289.9m

NYSE:MPLN

US$246.3m

NasdaqGS:HCAT

US$374.3m

NasdaqCM:OPRX

US$197.7m

価格と性能

最新ニュース

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors